研究方向一：靶向核药研究

    根据临床成像或治疗等应用需求，设计构建肿瘤特异性靶向的小分子、多肽及核酸适体等多价识别配体，设计新型螯合配体以实现温和条件下Ga-68、Lu-177及Ra-223等的直接标记或双功能螯合标记等高效标记。开展放射性核素诊疗药物临床前研究，主要内容包括理化性质评估、 生物分布研究、药效学研究、药代动力学研究、监测放射性药物的动态生物分布以及临床IIT实验。

 研究方向二：多特异性核酸适体

    发展多特异性核酸适体构建新方法，利用肿瘤细胞膜表面过表达的靶蛋白，实现多特异性核酸适体对肿瘤细胞多靶点的协同靶向识别，大幅提高核酸适体的识别精准性，获得新型分子识别工具。在此基础上，开发基于核酸适体的新型靶向药物递送体系，细胞膜表面蛋白的高效降解技术，靶向磁共振成像、靶向硼中子捕获治疗技术（BNCT）。

 研究方向三：化学发光新探针与精准成像

    设计和合成全新骨架的化学发光探针，通过结构优化精确调控化学发光探针的发射波长，量子产率等性质；通过特异性响应官能团的设计，实现活体内对酶、多肽、ROS等分子的精准活体成像，有助于理解生物体内的生物化学反应机制和生物分子的相互作用。应用新型化学发光探针开展疾病诊断研究、推动化学发光探针在生物医学领域的应用，实现技术的应用转化，为疾病的早期诊断和治疗提供精准成像工具。

 (1) Long-Term and Highly Sensitive Detection of Singlet Oxygen In Vivo With A Single Methylenecyclobutane Afterglow Probe，Yun Zhang, Yu-Ting He, Xuan He, Silin Huang*, and Xue-Qiang Wang*，CCS Chemistry, 2025, online, DOI: 10.31635/ccschem.025.202505498.

 (2) Aptamer Glue-Catalysis Enables Hyperefficient Targeted Membrane Protein Degradation,Guo-Rong Zhang, Chi Zhang, Ting Fu, Weihong Tan,  and  Xue-Qiang Wang*, JACS Au, 2024, 4, 2907–2914.

 (3) Chemical Tailoring of Aptamer Glues with Significantly Enhanced Recognition Ability for Targeted Membrane Protein Degradation，Zhang, Guo-Rong; Tan, Weihong; Wang, Xue-Qiang*，ACS Nano, 2023, 17, 15146-15154.

 (4) Regulating the Properties of XQ-2d for Targeted Therapeutic Agents Delivery to Pancreatic Cancer，Qiuxia Yang, Yongbo Peng, Zhengyu Deng, Dailiang Zhang, Cheng-Yu Long, Guo-Rong Zhang, Juan Li, Xue-Qiang Wang*,  Weihong Tan*，National Science Review, 2023,10, nwad113.

 (5) A Versatile Strategy for Convenient Circular Bivalent Functional Nucleic Acids Construction，Xiao-Jing Zhang, Zhuo Zhao, Xia Wang, Min-Hui Su, Yingying Li, Quan Yuan, Xue-Qiang Wang*, Weihong Tan，National Science Review, 2023, 10, nwac107.

 (6) Dual‐targeting Circular Aptamer Strategy Enabled Recognition of Different Leukemia Cells with Enhanced Binding Ability，Lili Ai, Tianhuan Peng, Yingying Li, Hailan Kuai, Yingyu Sima, Minhui Su, Dan Wang, Qiuxia Yang, Xue-Qiang Wang*, Weihong Tan，Angew. Chem. Int. Ed. 2022, 61, e202109500.

 (7) A new paradigm for artesunate anticancer function: considerably enhancing the cytotoxicity via conjugating artesunate with aptamer，Yingying Li, Y. Peng, Yan Tan, Wenjing Xuan, Ting Fu, Xue-Qiang Wang*, Weihong Tan*，Sig. Transduct. Target. Ther. 2021, 6, 327.

 (8) Regulating the Anticancer Efficacy of Sgc8–Combretastatin A4 Conjugates: A Case of Recognizing the Significance of Linker Chemistry for the Design of Aptamer-Based Targeted Cancer Therapy，Zhiyong Huang, Dan Wang, Cheng-Yu Long, Shen-Huan Li, Xue-Qiang Wang*, Weihong Tan* J. Am. Chem. Soc. 2021, 143, 8559–8564.

 (9) Molecularly Engineered  Aptamers Targeting Tumor Tissue and Cancer Cells for Efficient in vivo Recognition and Enrichment，Xia Wang, Xiao-Jing Zhang, Yingying Li, Guo-Rong Zhang, Juan Li, Xue-Qiang Wang*, Weihong Tan，CCS Chemistry, 2022, 4, 2581–2587.

 (10) Conjugating Aptamer and Mitomycin C with Reductant-Responsive Linker Leading to Synergistically Enhanced Anticancer Effect，Qiuxia Yang, Zhengyu Deng, Dan Wang, Jiaxuan He, Dailiang Zhang, Yan Tan, Tianhuan Peng， Xue-Qiang Wang*, Weihong Tan*，J. Am. Chem. Soc. 2020,  142, 2532-2540.

 (11) Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer，Jiaxuan He, Tianhuan Peng, Yongbo Peng, Lili Ai, Zhengyu Deng, Xue-Qiang Wang*, Weihong Tan*，J. Am. Chem. Soc. 2020, 142, 2532-2540.

 (12) Functional nucleic acids for cancer theranostics，Tianhuan Peng, Zhengyu Deng, Jiaxuan He, Yingying Li, Yan Tan, Yongbo Peng, Xue-Qiang Wang*,  Weihong Tan*，Coordination Chemistry Reviews, 2020, 43, 213080.